Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 31

1.

Parkinson's disease and resistive exercise: rationale, review, and recommendations.

Falvo MJ, Schilling BK, Earhart GM.

Mov Disord. 2008 Jan;23(1):1-11. Review.

PMID:
17894327
2.

[Motor symptoms in Parkinson disease].

Larsen JP, Beiske AG, Bekkelund SI, Dietrichs E, Tysnes OB, Vilming ST, Aasly JO.

Tidsskr Nor Laegeforen. 2008 Sep 25;128(18):2068-71. Review. Norwegian.

3.

The effects of exercise on balance in persons with Parkinson's disease: a systematic review across the disability spectrum.

Dibble LE, Addison O, Papa E.

J Neurol Phys Ther. 2009 Mar;33(1):14-26. doi: 10.1097/NPT.0b013e3181990fcc. Review.

PMID:
19265767
4.

Levodopa/dopamine replacement strategies in Parkinson's disease--future directions.

Olanow CW.

Mov Disord. 2008;23 Suppl 3:S613-22. doi: 10.1002/mds.22061. Review.

PMID:
18781663
5.

Potential therapeutic targets for Parkinson's disease.

Stoessl J.

Expert Opin Ther Targets. 2008 Apr;12(4):425-36. doi: 10.1517/14728222.12.4.425 . Review.

PMID:
18348679
7.

The search for biomarkers in Parkinson's disease: a critical review.

Antoniades CA, Barker RA.

Expert Rev Neurother. 2008 Dec;8(12):1841-52. doi: 10.1586/14737175.8.12.1841. Review.

PMID:
19086880
8.

[Non-motor disorders in Parkinson's disease].

Merello M.

Rev Neurol. 2008 Sep 1-15;47(5):261-70. Review. Spanish.

9.

Overview of Parkinson's disease.

Lew M.

Pharmacotherapy. 2007 Dec;27(12 Pt 2):155S-160S. Review.

PMID:
18041935
10.

Physical therapy in Parkinson's disease: evolution and future challenges.

Keus SH, Munneke M, Nijkrake MJ, Kwakkel G, Bloem BR.

Mov Disord. 2009 Jan 15;24(1):1-14. doi: 10.1002/mds.22141. Review.

PMID:
18946880
11.

Speech treatment for Parkinson's disease.

Ramig LO, Fox C, Sapir S.

Expert Rev Neurother. 2008 Feb;8(2):297-309. doi: 10.1586/14737175.8.2.297. Review.

PMID:
18271714
12.

Reevaluation of levodopa therapy for the treatment of advanced Parkinson's disease.

Yokochi M.

Parkinsonism Relat Disord. 2009 Jan;15 Suppl 1:S25-30. doi: 10.1016/S1353-8020(09)70008-2. Review.

PMID:
19131038
13.

Adenosine A2A receptor antagonists and Parkinson's disease: state of the art and future directions.

Simola N, Morelli M, Pinna A.

Curr Pharm Des. 2008;14(15):1475-89. Review.

PMID:
18537671
14.
15.

The basal ganglia circuits, dopamine, and ambiguous word processing: a neurobiological account of priming studies in Parkinson's disease.

Chenery HJ, Angwin AJ, Copland DA.

J Int Neuropsychol Soc. 2008 May;14(3):351-64. doi: 10.1017/S1355617708080491. Review.

PMID:
18419834
16.

Impulse-control disorders in Parkinson's disease.

Ferrara JM, Stacy M.

CNS Spectr. 2008 Aug;13(8):690-8. Review.

PMID:
18704024
17.

Exercise and neuroplasticity in persons living with Parkinson's disease.

Hirsch MA, Farley BG.

Eur J Phys Rehabil Med. 2009 Jun;45(2):215-29. Review.

18.

Parkinson's disease: emerging pharmacotherapy.

Strecker K, Schwarz J.

Expert Opin Emerg Drugs. 2008 Dec;13(4):573-91. doi: 10.1517/14728210802596906 . Review.

PMID:
19046128
19.

Impact of physical therapy for Parkinson's disease: a critical review of the literature.

Kwakkel G, de Goede CJ, van Wegen EE.

Parkinsonism Relat Disord. 2007;13 Suppl 3:S478-87. doi: 10.1016/S1353-8020(08)70053-1. Review.

PMID:
18267287
20.

Mechanisms compensating for dopamine loss in early Parkinson disease.

Brotchie J, Fitzer-Attas C.

Neurology. 2009 Feb 17;72(7 Suppl):S32-8. doi: 10.1212/WNL.0b013e318198e0e9. Review.

PMID:
19221312

Supplemental Content

Support Center